Study of the Efficacy and Safety of Tezosentan in Patients With Pre-operative Pulmonary Hypertension, Due to Left Heart Disease, Undergoing Open Heart Surgery

Not Recruiting

Trial ID: NCT00458276

Age - 18 Years-N/A Gender - All Accepting Healthy Volunteers - No

Purpose

Endothelin-1 is a powerful substance that may be involved in causing hemodynamic instability (problems related to unstable blood pressure) during and after open heart surgery. Tezosentan is an investigational intravenous drug that blocks the endothelin receptors. This clinical trial will assess the potential benefit of tezosentan compared with placebo in the treatment of patients undergoing open heart surgery with cardiopulmonary bypass (CPB). Treatment time is from the start of surgery up to 24 hours.

Official Title

Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of Tezosentan in Patients With Pre-operative Pulmonary Hypertension, Due to Left Heart Disease, Undergoing Cardiac Surgery

Stanford Investigator(s)

Ronald Pearl
Ronald Pearl

Dr. Richard K. and Erika N. Richards Professor

Eligibility


Inclusion Criteria:

   - Patients ≥ 18 years of age

   - Male or female patients (females of child-bearing potential must have been surgically
   sterilized or use a reliable method of contraception).

   - Patients undergoing complex* cardiac surgery on CPB and having systolic PAP > 40 mmHg
   or mean PAP > 30 mmHg (*surgery on 2 valves, 1 valve and revascularization, or
   reoperation of a valve)

   - Patients undergoing cardiac surgery on CPB and having pre-operative pulmonary
   hypertension due to left heart disease with systolic PAP > 60 mmHg

   - Signed written informed consent

Exclusion Criteria:

   - Systolic blood pressure < 100 mmHg

   - Significant chronic lung disease

   - Emergency surgery

   - Pregnant/breast-feeding

   - Investigational drug use within 28 days prior to randomization

   - Complex adult congenital heart disease.

   - Severe concomitant illness limiting life expectancy to < 6 months

   - Participation in a device study that will affect the outcome of the study

   - Pre-operative use of balloon pump, inotropes/vasopressors, treatment of pulmonary
   arterial hypertension

   - Known hypersensitivity to tezosentan or drugs of the same class, or any of their
   excipients

   - Severe liver impairment

View More
View Less

Intervention(s):

drug: tezosentan

drug: placebo

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305

©2024 Stanford Medicine